LCM
PSTX

Laurion Capital Management’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Laurion Capital Management’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-545,700
Closed -$1.68M – 709
2023
Q1 		$1.68M Hold
545,700
– – 0.01% 281
2022
Q4 		$2.89M Hold
545,700
– – 0.01% 292
2022
Q3 		$1.93M Hold
545,700
– – 0.01% 330
2022
Q2 		$1.41M Buy
+545,700
New +$1.52M 0.02% 256

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Laurion Capital Management's PSTX Position: Q2 2023 in Review

Laurion Capital Management sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q2 2023, closing a stake of 545,700 shares — an estimated $1.68M sold.

Laurion Capital Management first reported a position in PSTX in Q2 2022 and held it in 4 quarters. The position peaked at $2.89M in Q4 2022. 94 funds tracked by Wall St. Rank hold PSTX as of Q2 2023.

  • Laurion Capital Management reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Laurion Capital Management sold 545,700 Poseida Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $1.68M.
  • Laurion Capital Management first reported a position in Poseida Therapeutics, Inc. Common Stock in Q2 2022 and held it in 4 quarters.
  • Laurion Capital Management's Poseida Therapeutics, Inc. Common Stock position peaked at $2.89M in Q4 2022.
  • 94 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Laurion Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.